PARP1 and breast carcinoma: Thus, PARP inhibition caused by FDA-approved PARP inhibitor (PARPi) drugs (e.g., olaparib, iniparib) potentiate the effects of DNA-damaging agents and ionizing radiations in the therapy of TNBC, especially BRCA-associated breast cancer [217,218,219].